Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure (HF) with left ventricular systolic dysfunction (LVSD) is a major cause of cardiovascular morbidity and mortality.
• Angiotensin-converting enzyme inhibitors (ACE-Is) and beta-adrenergic receptor blockers (BBs) are foundational therapies for HF-LVSD.
• Other agents like angiotensin receptor blockers and aldosterone blockers also demonstrate efficacy.

Purpose of the Study:

• To review the efficacy and safety of adding a further renin-angiotensin-aldosterone system (RAAS) inhibitor or blocker.
• To evaluate these intensified regimens in patients with HF-LVSD already treated with ACE-I or angiotensin receptor blocker plus BB therapy.

Main Methods:

• Literature review of studies investigating additional RAAS blockade in HF-LVSD.
• Analysis of efficacy and safety data from relevant clinical trials.

Main Results:

• The addition of another RAAS inhibitor or blocker to standard ACE-I or ARB plus BB therapy in HF-LVSD requires careful consideration.
• Evidence on the incremental benefit and potential risks of such intensified RAAS blockade is reviewed.

Conclusions:

• Clinicians must weigh the potential benefits against the risks when considering intensified RAAS blockade for HF-LVSD.
• Further research may be needed to clarify the optimal role of additional RAAS inhibition in specific HF patient populations.